Form 4: Estrella Immunopharma CFO Reports Stock Transaction
Insider Transaction (Form 4)
Jiandong Xu, Chief Financial Officer of Estrella Immunopharma, Inc., reported multiple transactions in common stock on August 18, 2026.
Summary
- Option exercise/conversion: acquired 100,000 Common Stock, par value $0.0001 per share at $0.81 ($81,500) on August 18, 2026; holds 365,488 after (Direct).
- Option exercise/conversion: disposed of 100,000 Incentive Share Option on August 18, 2026; holds 390,796 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jiandong Xu — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-18 | Option exercise/conversion | Common Stock, par value $0.0001 per share | 100,000 | $1 | $81.5K | 365,488 |
| 2026-08-18 | Option exercise/conversion | Incentive Share Option | 100,000 | — | — | 390,796 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-18 | Option exercise/conversion (100,000 shares) |
| 2026-08-18 | Option exercise/conversion (100,000 shares) |
Keywords
insider transaction, Form 4, ESLA, Estrella Immunopharma, Inc., neutral, Jiandong Xu
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.